Print this page    •   Back to Web version of article

Tell Johnson & Johnson to Stop Turning Its Back on AIDS Patients
J&J Is Undermining Access to Key AIDS Drugs

December 15, 2011

Tell Johnson & Johnson to Stop Turning Its Back on AIDS Patients

On Monday, December 19, pharmaceutical giant Johnson & Johnson is expected to announce whether it intends to license its patents on three lifesaving HIV/AIDS drugs to the Medicines Patent Pool, a mechanism designed to lower prices of HIV medicines and increase access to them for people in the developing world.

The time to act is now!

Tell J&J to join the patent pool

Over the past two years, Doctors Without Borders/Médecins Sans Frontières (MSF) has been urging Johnson & Johnson to take this critical step.

Johnson & Johnson has so far refused to join discussions on licensing these patents to the Medicines Patent Pool. The Pool has been set up to increase access to more affordable versions of HIV drugs, including fixed-dose combinations that include multiple medicines in one pill, and to develop much-needed pediatric HIV drugs.

The Pool would license patents on HIV drugs to other manufacturers and the resulting competition would dramatically reduce prices, making them much more affordable in the developing world. However, since the Pool is voluntary it will only work if patent holders like Johnson & Johnson choose to participate.




This article was provided by Doctors Without Borders. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/65205/tell-johnson-johnson-to-stop-turning-its-back-on.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.